Taysha Gene Therapies Overview
Taysha Gene Therapies Target Price
Analysts' 12-month price predictions for TSHA.
Get informed when a big investor buys or sells
+ FollowShare Price
$5.7
Average Target Price
$14.50
154.4% upside
154.4% upside2 analysts in the last 4 months
High: $15 | Low: $14
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-30 | Robert W. Baird | $15 | 163.2% upside |  |
| 2026-06-23 | Pivotal ResearchKeith Tapper | $14 | 145.6% upside | |
| 2026-01-06 | Raymond JamesChris Raymond | $13 | 128.1% upside | |
| 2026-01-05 | Wells FargoZachary Fadem | $11 | 93% upside | |
| 2025-12-04 | Goldman Sachs | $11 | 93% upside | |
| 2025-12-04 | UBS | $11 | 93% upside | |
| 2025-11-14 | Cantor FitzgeraldKristen Kluska | $13 | 128.1% upside | |
| 2025-11-05 | JMP Securities | $8 | 40.4% upside | |
| 2025-10-02 | Robert W. BairdJack Allen | $12 | 110.5% upside | |
| 2025-10-02 | NeedhamGil Blum | $10 | 75.4% upside | |
| 2024-08-14 | BMO CapitalKeith Tapper | $5 |  12.3% downside | |
| 2024-07-01 | Piper SandlerChristopher Raymond | $7 | 22.8% upside | |
| 2024-05-14 | JefferiesEun Yang | $8 | 40.4% upside | |
| 2024-04-09 | Raymond JamesChristopher Raymond | $9 | 57.9% upside | |
| 2023-02-01 | Jefferies | $1.5 | 73.7% downside | |
| 2021-10-19 | Morgan StanleyMatthew Harrison | $39 | 584.2% upside | |
| 2021-05-19 | Cantor FitzgeraldKristen Kluska | $44 | 671.9% upside | |